These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15671653)

  • 1. Nonradioactive rubidium ion efflux assay and its applications in drug discovery and development.
    Terstappen GC
    Assay Drug Dev Technol; 2004 Oct; 2(5):553-9. PubMed ID: 15671653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High throughput assay technologies for ion channel drug discovery.
    Zheng W; Spencer RH; Kiss L
    Assay Drug Dev Technol; 2004 Oct; 2(5):543-52. PubMed ID: 15671652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of an atomic absorption rubidium ion efflux assay for KCNQ/M-channels using the ion Channel Reader 8000.
    Wang K; McIlvain B; Tseng E; Kowal D; Jow F; Shen R; Zhang H; Shan QJ; He L; Chen D; Lu Q; Dunlop J
    Assay Drug Dev Technol; 2004 Oct; 2(5):525-34. PubMed ID: 15671650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis of large conductance Ca2(+)-activated K(+) channels: ion flux studies by atomic absorption spectrometry.
    Parihar AS; Groebe DR; Scott VE; Feng J; Zhang XF; Warrior U; Gopalakrishnan M; Shieh CC
    Assay Drug Dev Technol; 2003 Oct; 1(5):647-54. PubMed ID: 15090237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ion channel profiling to advance drug discovery and development.
    Zou B
    Drug Discov Today Technol; 2015 Nov; 18():18-23. PubMed ID: 26723888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic scope of modulation of non-voltage-gated cation channels.
    Li S; Gosling M; Poll CT; Westwick J; Cox B
    Drug Discov Today; 2005 Jan; 10(2):129-37. PubMed ID: 15718162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic scope of modulation of non-voltage-gated cation channels.
    Li S; Gosling M; Poll CT; Westwick J; Cox B
    Drug Discov Today; 2004 Dec; 9(24):1045-54. PubMed ID: 15582793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rb+ efflux assay for assessment of non-selective cation channel activities.
    Liu K; Samuel M; Harrison RK; Paslay JW
    Assay Drug Dev Technol; 2010 Jun; 8(3):380-8. PubMed ID: 20085483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flux assays in high throughput screening of ion channels in drug discovery.
    Gill S; Gill R; Lee SS; Hesketh JC; Fedida D; Rezazadeh S; Stankovich L; Liang D
    Assay Drug Dev Technol; 2003 Oct; 1(5):709-17. PubMed ID: 15090243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of kappa-conotoxin PVIIA to Shaker K+ channels reveals different K+ and Rb+ occupancies within the ion channel pore.
    Boccaccio A; Conti F; Olivera BM; Terlau H
    J Gen Physiol; 2004 Jul; 124(1):71-81. PubMed ID: 15226365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting high-throughput ion channel screening technologies in integrated drug discovery.
    Treherne JM
    Curr Pharm Des; 2006; 12(4):397-406. PubMed ID: 16472135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology.
    Dunlop J; Bowlby M; Peri R; Vasilyev D; Arias R
    Nat Rev Drug Discov; 2008 Apr; 7(4):358-68. PubMed ID: 18356919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predict potential drug targets from the ion channel proteins based on SVM.
    Huang C; Zhang R; Chen Z; Jiang Y; Shang Z; Sun P; Zhang X; Li X
    J Theor Biol; 2010 Feb; 262(4):750-6. PubMed ID: 19903486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel fluorescent proteins for high-content screening.
    Wolff M; Wiedenmann J; Nienhaus GU; Valler M; Heilker R
    Drug Discov Today; 2006 Dec; 11(23-24):1054-60. PubMed ID: 17129823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an HTS assay for Na+, K+-ATPase using nonradioactive rubidium ion uptake.
    Gill S; Gill R; Wicks D; Despotovski S; Liang D
    Assay Drug Dev Technol; 2004 Oct; 2(5):535-42. PubMed ID: 15671651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A decade of fragment-based drug design: strategic advances and lessons learned.
    Hajduk PJ; Greer J
    Nat Rev Drug Discov; 2007 Mar; 6(3):211-9. PubMed ID: 17290284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in electrophysiology-based screening technology and the impact upon ion channel discovery research.
    Southan A; Clark G
    Methods Mol Biol; 2009; 565():187-208. PubMed ID: 19551363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of statistical 'design of experiments' methods in drug discovery.
    Tye H
    Drug Discov Today; 2004 Jun; 9(11):485-91. PubMed ID: 15149624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel high-throughput screening assay for HCN channel blocker using membrane potential-sensitive dye and FLIPR.
    Vasilyev DV; Shan QJ; Lee YT; Soloveva V; Nawoschik SP; Kaftan EJ; Dunlop J; Mayer SC; Bowlby MR
    J Biomol Screen; 2009 Oct; 14(9):1119-28. PubMed ID: 19773585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.